Barclays Maintains Overweight on Teladoc Health, Lowers Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Steve Valiquette maintains an Overweight rating on Teladoc Health (NYSE:TDOC) but lowers the price target from $20 to $10.
August 01, 2024 | 3:47 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Barclays analyst Steve Valiquette maintains an Overweight rating on Teladoc Health but lowers the price target from $20 to $10.
The lowered price target from $20 to $10 suggests a less optimistic outlook for Teladoc Health's stock performance, which could lead to a short-term decline in its stock price despite the maintained Overweight rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100